Microfluidic cell-squeezing device opens new possibilities for cell-based vaccines
MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system’s B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines.
Such vaccines, created by reprogramming a patient’s own immune cells to fight invaders, hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic, and only one therapy has been approved by the Food and Drug Administration.
While most of these vaccines are created with dendritic cells, a class of antigen-presenting cells with broad functionality in the immune system, the researchers demonstrate in a study published in Scientific Reports that B cells can be engineered to serve as an alternative.
“We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells,” says Gregory Szeto, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and the paper’s lead author.
Darrell Irvine, a member of the Koch Institute and a professor of biological engineering and of materials sciences and engineering, is the paper’s senior author.
A new vaccine-preparation approach
Dendritic cells are the most naturally versatile antigen-presenting cells. In the body, they continuously sample antigens from potential invaders, which they process and present on their cell surface. The cells then migrate to the spleen or the lymph nodes, where they prime T cells to mount an attack against cells that are cancerous or infected, targeting the specific antigens that are ingested and presented.
Despite their critical role in the immune system, dendritic cells have drawbacks when used for cell-based vaccines: They have a short lifespan, they do not divide when activated, and they are relatively sparse in the bloodstream.
B cells are also antigen-presenting cells, but in contrast to dendritic cells, they can proliferate when activated and are abundant in the bloodstream. However, their functionality is more limited: Whereas dendritic cells constantly sample antigens they encounter, a B cell is genetically programmed only to bind to a specific antigen that matches the receptor on its surface. As such, a B cell generally will not ingest and display an antigen if it does not match its receptor.
Using a microfluidic device, MIT researchers were able to overcome this genetically programmed barrier to antigen uptake — by squeezing the B cells.
Through “CellSqueeze,” the device platform originally developed at MIT, the researchers pass a suspension of B cells and target antigen through tiny, parallel channels etched on a chip. A positive-pressure system moves the suspension through these channels, which gradually narrow, applying a gentle pressure to the B cells. This “squeeze” opens small, temporary holes in their membranes, allowing the target antigen to enter by diffusion.
This process effectively loads the cells with antigens to prime a response of CD8 — or “killer” — T cells, which can then kill cancer cells or other target cells.
Read more: Freshly squeezed vaccines
The Latest on: Cell-based vaccines
via Google News
The Latest on: Cell-based vaccines
- Hyris' New T-Cell Test is Finally Available to EU Countries to Easily Map Patients' Cellular Immunity to SARS-CoV-2on August 5, 2022 at 5:00 am
After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR ...
- Cancer latest: HPV jab may ward off cervical cancer in women with precancerous cellson August 5, 2022 at 4:39 am
CANCER can appear anywhere on the body and present with a range of symptoms. While some are more prevalent than others, each in their own way presents a real danger. Cervical cancer is one of those ...
- Change in monkeypox vaccine injection method could mean more doses but may not be easy, experts sayon August 4, 2022 at 3:38 pm
As part of the Biden administration's declaration of the monkeypox outbreak in the US as a public health emergency, it's looking into administering Jynneos vaccine shots intradermally instead of ...
- Monkeypox vaccines: A virologist answers 6 questions about how they work, who can get them and how well they prevent infectionon August 4, 2022 at 1:44 pm
The Jynneos monkeypox vaccine provides strong protection against infection but is in short supply. Mario Tama/Getty ImagesMonkeypox isn’t going to be the next COVID-19. But with the outbreak having ...
- Misrepresentation of Germany’s Data on Unverified COVID-19 Vaccine Side Effectson August 3, 2022 at 12:26 pm
Viral claims have repeatedly misrepresented unverified data from a U.S. vaccine safety system that encourages reports of any potential side effects -- whether they're likely to be caused by the ...
- Role of Computer Modeling in Vaccine Developmenton August 3, 2022 at 7:05 am
Vaccines are regarded as the safest and most cost-effective approach against disease and have changed the way we live our lives.
- New Respiratory Syncytial Virus Vaccine Works in Miceon August 2, 2022 at 5:08 pm
Respiratory syncytial virus (RSV) is a major cause of infant hospitalization and a leading cause of death around the world in children under age 5. | Immunology ...
- NorthShore agrees to pay $10.3 million settlement in COVID-19 vaccine lawsuit over religious exemptionson August 2, 2022 at 10:17 am
As part of the settlement, NorthShore is agreeing to re-hire workers who were fired for refusing to get vaccinated for religious reasons.
- Scientists develop effective intranasal mumps-based COVID-19 vaccine candidateon July 27, 2022 at 1:27 pm
New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger ...
- New class of nanoparticle-based vaccines could help immunize against canceron July 27, 2022 at 5:10 am
A vaccination as tumor therapy—with a vaccine individually created from a patient's tissue sample that "attaches" the body's own immune system to cancer cells. The basis for this long-term vision has ...
via Bing News